Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo
- 434 Downloads
Patupilone is a microtubule stabilizer (MTS) currently in clinical development. Here, we evaluate the anti-cancer activity in vitro and in vivo in comparison to paclitaxel and describe the pharmacokinetics (PK) of patupilone in tumor-bearing nude mice and rats.
The potency in vitro of patupilone and two other MTS, paclitaxel and ixabepilone, was determined using human colon carcinoma cell lines with low (HCT-116, HT-29, RKO) and high (HCT-15) P-glycoprotein expression (P-gp), as well as two multi-drug resistance (MDR) model cell pairs, MCF7/ADR and KB-8511 cells and their respective drug-sensitive parental counterparts. The PK of patupilone was investigated in nude mice bearing HCT-15 or HT-29 xenografts and in rats bearing s.c. pancreatic CA20498 tumors or A15 glioma tumors. Anti-cancer activity in vivo was compared to that of paclitaxel using three different human tumor colon models. The retention and efficacy of patupilone was compared in small and large HT-29 xenografts whose vascularity was determined by non-invasive magnetic resonance imaging.
Patupilone was highly potent in vitro against four different colon carcinoma cell lines including those showing multi-drug-resistance. In contrast, paclitaxel and ixabepilone displayed significantly reduced activity with markedly increased resistance factors. In both rats and mice, a single i.v. bolus injection of patupilone (1.5–4 mg/kg) rapidly distributed from plasma to all tissues and was slowly eliminated from muscle, liver and small intestine, but showed longer retention in tumor and brain with no apparent elimination over 24 h. Patupilone showed significant activity against three human colon tumor models in vivo, unlike paclitaxel, which only had activity against low P-gp expressing tumors. In HT-29 tumors, patupilone activity and retention were independent of tumor size, blood volume and flow.
The high potency of patupilone, which is not affected by P-gp expression either in vitro or in vivo, and favorable PK, independent of tumor vascularity, suggest that it should show significant activity in colorectal cancer and in other indications where high P-gp expression may compromise taxane activity.
KeywordsPatupilone Pharmacokinetics Colon cancer P-glycoprotein Tumor vasculature
We thank Mike Becquet, Mark Hattenberger, Melanie Muller, Samuel Kunz, Fabienne Schaeffer, Julian Vaxelaire, Robert Reuter and Jacqueline Loretan for their excellent technical support.
- 8.Tanabe KM, Millward M, Allen JD (2005) Interactions of patupilone (epothilone B) with multidrug transporter proteins. Proceedings of the 96th annual meeting AACR, Ananheim, CA; Apr 16–20, p. 809Google Scholar
- 15.Melichar B, Casado Er, Tabernero J, et al. Patupilone in chemotherapy-pretreated patients with advanced colorectal cancer (CRC) receiving nutritional support and intensive diarrea management: a phase I multicenter trial. Ann Oncol 2006; 17 (Supplement 9), Abstract 31st ESMO congressGoogle Scholar
- 24.Meyer T, Regenass U, Fabbro D, Alteri E, Rösel J, Müller M, Caravatti G, Matter A (1989) A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumor activity. Int J Cancer 43:851–856PubMedCrossRefGoogle Scholar
- 27.Blum W, Aichholz R, Ramstein P, Kühnol J, Brüggen J, O’Reilly T, Flörsheimer A (2001) In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry. Rapid Commun Mass Spectrom 15(1):41–49PubMedCrossRefGoogle Scholar
- 37.Saulnier M, Roman D, Mahl A et al (2003) Integrative toxicological and pharmacogenomic investigations of intestinal effects induced by epothilone B after single intraveneous administration in rats. Clin Cancer Res 9(16, part 2):A270Google Scholar